We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Netrin-1 Promotes Atherosclerosis by Inhibiting the Emigration of Macrophages from Plaques

By LabMedica International staff writers
Posted on 22 Feb 2012
Cardiovascular disease researchers have identified a molecular signal that promotes the blockage of arteries by preventing migration of macrophages away from atherosclerotic plaques.

The signaling molecule is the protein netrin-1. More...
The netrin family is composed mostly of secreted proteins that normally serve as bifunctional signals during development of the embryonic brain. Expressed in the midline of all animals possessing bilateral symmetry, they can act as long or short-range signals during neurogenesis. In order to carry out their functions, netrins interact with specific receptors: DCC or UNC-5 depending on whether they are trying to attract or repel neurons respectively. The C-terminal domain of the netrins is where most of the variation is found between species and it contains different amino acids that allow interaction with specific proteins in extracellular matrix or on cell surface. The differences in terms of structure and function have led to the identifications of several different types of netrins including netrin-1, netrin-3, and netrins-G.

Investigators at the New York University School of Medicine (New York, USA) used fluorescence microscopy techniques to trace the movement of macrophages towards and away from plaques that had formed in arterial tissue taken from mice deficient in the receptor for low-density lipoprotein. Arterial tissues taken from animals genetically engineered to lack macrophage netrin-1expression were also examined.

Results published in the January 8, 2012, online edition of the journal Nature Immunology revealed that acting via its receptor protein, UNC5b, netrin-1 inhibited the migration of macrophages directed by the chemokines CCL2 (chemokine (C-C motif) ligand 2) and CCL19 (chemokine (C-C motif) ligand 19), as well as activation of the actin-remodeling GTPase Rac1 and actin polymerization. Genetically engineered deletion of netrin-1 in macrophages resulted in much less atherosclerosis in mice deficient in the receptor for low-density lipoprotein and promoted the emigration of macrophages from plaques.

The finding that netrin-1 promoted atherosclerosis by retaining macrophages in the artery wall prompted the investigators to conclude that, “Our results establish a causative role for negative regulators of leukocyte migration in chronic inflammation. Local inhibition of such factors may have therapeutic value for the resolution of inflammation in atherosclerosis and other chronic inflammatory diseases.”

Related Links:

New York University School of Medicine




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.